Four years after Sanofi shelled out $125 million for global rights to Biond Biologic | The company is handing back the tumor ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

The FDA granted approval of Merilog to Sanofi (SNY)-Aventis U.S. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top ...

A year and a half after Sanofi swooped in on Johnson & Johnson’s dismantled vaccines unit to pick up an E. coli candidate, the asset has failed its phase 3 trial. A scheduled review by the study ...

Novavax on Thursday posted a narrower fourth-quarter loss and said it expects its licensing deal with French drugmaker Sanofi ...

Metabolex has entered into an agreement with Sanofi–Aventis for the development of small molecules that target G protein-coupled receptor 119 (GPR119), the most advanced of which is in a Phase ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the ...